An investment firm based in the Middle East is a premier investment company with a diverse portfolio spanning multiple asset classes, including real assets and alternative investments. The firm’s vision is to become a leading integrated solutions provider in cell and gene therapy, establishing itself as the first globally trusted partner in precision medicine within the Middle East. The firm focuses on providing research, manufacturing, and a comprehensive range of services related to genomic medicine, targeting local, regional, and international markets. Check sizes vary and are flexible but on average range between USD $5–10M. In alignment with national strategic initiatives, the firm aims to act as a catalyst for developing this vital industry and emphasizes the importance of the private sector in supporting emerging, innovative sectors. The firm aspires to accelerate the delivery of groundbreaking innovations and ensure patient access to treatments for chronic and rare diseases while contributing to the localization of the biotechnology industry and building national expertise to achieve these ambitious goals. 

Within therapeutics, the firm is focused on cell and gene therapy in IND, Phase 1, and/or moving into Phase 2. There are several indications of interest, including orphan diseases, oncology, neurology, immunology, cardiovascular diseases, and diabetes. For tech-driven biosciences, the firm is interested in AI-driven platforms for drug discovery and clinical development. 

The firm is only interested in companies willing to work toward the goal of bringing biotech innovation to the region through manufacturing and clinical development. A carve-out or partnership in the region is necessary. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A specialized venture fund with a single limited partner leverages deep expertise in transfusion medicine, cell therapy, and hematology. The firm launched a fund dedicated to early-stage life science investments from Series A to C and has made multiple investments to date. While primarily focused on U.S.-based companies, the firm remains open to global opportunities. 

The firm has four key areas of focus: benign hematology, transfusion medicine, cell therapy, and infectious diseases. The firm is open to therapeutics, diagnostics, and medical devices. Within therapeutics, the firm considers most modalities and prefers programs that are clinical stage or near-clinical stage (IND-ready or submitted). Within diagnostics, the firm prefers technologies at the clinical stage or on the market, with proof of concept demonstrated. Within medical devices, the firm is open to all technologies but is particularly interested in cell therapy-enabling technologies at the clinical stage or on the market, with proof of concept established. With a focus on the need for blood-related and cellular technologies, the firm seeks investments that not only generate financial returns but also align with a humanitarian mission to advance healthcare access and innovation. 

The firm values working with management teams that are fully committed to their projects. The firm prefers teams with a balanced mix of scientific and commercial expertise and takes a collaborative approach as a strategic co-investor, engaging closely with the subject-matter experts within each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in the US. The firm invests in companies focused on cancer-related data accessibility and scalability, infrastructure, education and access, and IT and service solutions that aim to transform the way cancer care is designed and delivered at scale. Drugs, therapeutics, or medical devices are not areas of interest for the firm. 

The firm invests in Seed stage companies that are currently selling in the market and is open to opportunities globally. Typical allocations range between $250,000 and $1.5 million USD. The firm can act as both a lead investor and a co-investor. 

Within the life sciences sector, the firm focuses exclusively on cancer-oriented digital health companies and does not invest in drugs, therapeutics, medical devices, or technologies that require FDA approval. However, the firm plans for future funds to expand into FDA-regulated technologies. 

The firm does not have specific management team requirements and does not require a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital investor with more than $1 billion in funding that helps founders bring therapeutic ideas to clinical proof-of-concept in a capital-efficient model. The firm provides portfolio companies with both capital and access to an experienced team of drug developers and biotech operators who deliver tailored operational and scientific support. 

The firm invests in therapeutics companies at the Seed ($5–12 million) or Series A ($15–25 million) stage and is also open to spinout opportunities. The firm can be first or second money in and is geography-agnostic. 

The firm solely invests in therapeutics and is modality- and indication-agnostic. Companies can be single-asset or platform-focused. The firm will fund anything from a well-defined idea on paper to existing companies with significant proof-of-concept data or early clinical data. 

The firm does not have specific management team requirements and typically acts as a lead investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A seed and early-stage venture investor and invests in disruptive technologies with focus on highly scalable Health Tech and ICT models. The typical investment size ranges from €0.5 million to € 5 million. The firm invests only in companies based in Europe. 
 
The firm is currently looking for new opportunities and focuses on companies developing biotech enabling platforms, diagnostics, digital health solutions and minimally to non/minimal-invasive medical devices. The firm will not invest in pure drug development companies without underlying platform technology. 
 
The firm typically seeks to invest in private companies with convincing founder teams. The firm will consider pre-revenue companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital fund makes equity investments ranging from €500,000 to €5 million, with additional capital reserved for follow-on financing. The firm invests in companies across Europe and selectively in the United States. 

The firm is currently seeking opportunities in the sectors of BioTools, Labtech, TechBio, Medical Technology, Biotech, and Diagnostics. The firm prefers companies that have already established proof of concept. 

The firm focuses on privately held companies and does not require high-profile management teams to be in place. The firm generally takes a board seat following investment and prefers to act as the lead investor. The firm targets companies that already have a commercially viable technology, product, or service, ideally with a first collaboration or pilot with a potential customer, and that can reach commercialization with total investment between €10 million and €50 million. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.